Is CABA Worth Buying in 2026?

Cabaletta Bio, Inc. Common Stock

STOCK BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Updated 2026-08-16

Here’s whether Cabaletta Bio, Inc. Common Stock (CABA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.

🔴
Bearish

Positives: RSI 52 — healthy momentum range; strong 1-year return of +66.7%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-5.96% over 10 days); 3-month momentum negative (-16.9%). Currently 35.0% off its 52-week high. Score: -3/7.

Ready to act on this? 📈 Trade on Webull

CABA is trading below its 200-day MA ($2.86) — a key warning sign the longer-term trend is under pressure. An RSI of 52.0 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +66.7% compares to +20.4% for SPY (beat the market by 46.3%). The current 35.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $16,667 today
vs. S&P 500 (SPY) — same period beat market by 46.3%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($2.86)
Above 50-day MA ($2.90)
RSI(14) neutral zone (30–70) — currently 52.0
Positive return (+66.7%)
!Within 10% of period high (−35.0%)
Period Range $2.75
$1.40 $4.23
RSI (14) 52.0
0 · OversoldOverbought · 100

Key Metrics

Price$2.75
Period Return+66.7%
Period High$4.23
Period Low$1.40
Drawdown−35.0%
MA-50$2.90
MA-200$2.86
RSI (14)52.0
Avg Volume (30d)3.6M
vs. SPYbeat by 46.3%
Return Rank#226 of 1252

Trade CABA

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers